Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H11NO2 |
Molecular Weight | 189.2105 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(=O)CC(C1=O)C2=CC=CC=C2
InChI
InChIKey=WLWFNJKHKGIJNW-UHFFFAOYSA-N
InChI=1S/C11H11NO2/c1-12-10(13)7-9(11(12)14)8-5-3-2-4-6-8/h2-6,9H,7H2,1H3
Molecular Formula | C11H11NO2 |
Molecular Weight | 189.2105 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://www.drugbank.ca/drugs/DB00832Curator's Comment: description was created based on several sources, including:
http://www.druglib.com/activeingredient/phensuximide/
Sources: http://www.drugbank.ca/drugs/DB00832
Curator's Comment: description was created based on several sources, including:
http://www.druglib.com/activeingredient/phensuximide/
Phensuximide is an anticonvulsant in the succinimide class. For the treatment of epilepsy. Phensuximide suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in absence (petit mal) seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex. Phensuximide's mechanism of action not understood, but may act in inhibitory neuronal systems that are important in the generation of the three per second rhythm. It's effects may be related to its ability to inhibit depolarization-induced accumulation of cyclic AMP and cyclic GMP in brain tissue.
Originator
Approval Year
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/116142/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENSUXIMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:28:28 GMT 2023
by
admin
on
Fri Dec 15 15:28:28 GMT 2023
|
Record UNII |
6WVL9C355G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C264
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
||
|
WHO-VATC |
QN03AD02
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
||
|
WHO-ATC |
N03AD02
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
513
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
PHENSUXIMIDE
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
m8643
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
201-664-6
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
34367-67-4
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
SUPERSEDED | |||
|
100000082262
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
C66375
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
86-34-0
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
6WVL9C355G
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
DTXSID4023460
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
33309
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB09783MIG
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
2139
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL797
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
1528002
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
6839
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
DB00832
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
760079
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY | |||
|
C100129
Created by
admin on Fri Dec 15 15:28:28 GMT 2023 , Edited by admin on Fri Dec 15 15:28:28 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |